Visus Therapeutics
Latest round
- Series A
Last raised
- Aug 2021
Total raised
- $56M
Investors
- 5
About Visus Therapeutics
Based in Washington, US, and founded in 2019 by Benjamin Bergo, Visus Therapeutics operates as a clinical-stage pharmaceutical company that develops presbyopia-correcting eye drop for patients' eye vision. The company has offices in Seattle, Washington, and Orange County, California. Further, in September 2022, Visus Therapeutics acquired ViewPoint Therapeutics from Asset Management Ventures, BVF Partners, Lagunita BioSciences, Mission Bay Capital, etc. Visus Therapeutics, Inc. provides VTI-001 (BRIMOCHOL™) and VTI-003 that help billions of adults who suffer from presbyopia, known as loss of near vision. The lead clinical candidate is VTI-001 (BRIMOCHOL™), a daily eye drop designed to correct the loss of near vision associated with presbyopia. The company is specialized in Presbyopia, Ophthalmology, Optometry, and Eye Health.
Who invested in Visus Therapeutics
5 investors across 2 rounds
See all investors in Visus Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Visus Therapeutics
Who invested in Visus Therapeutics?
Visus Therapeutics has 5 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Visus Therapeutics raised?
Visus Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Visus Therapeutics last raise money?
Visus Therapeutics's most recent round on record is a Series A, in Aug 2021.
What does Visus Therapeutics do?
Based in Washington, US, and founded in 2019 by Benjamin Bergo, Visus Therapeutics operates as a clinical-stage pharmaceutical company that develops presbyopia-correcting eye drop for patients' eye vision.
Where is Visus Therapeutics headquartered?
Visus Therapeutics is headquartered in Seattle, US.
Which VCs invest in companies like Visus Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Visus Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Visus Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.